CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE: The level of the degradation product Benzaldehyde is out of specification in the affected lots.
Brand(s)
Last updated
Summary
Product
CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE
Issue
Health products - Product quality
What to do
Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
Affected products
| Brand | Product name | Market Authorization | Dosage Form | Strength | Lot |
|---|---|---|---|---|---|
| CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE | CISATRACURIUM BESYLATE INJECTION USP MULTIDOSE | DIN 02408813 | Solution | Cisatracurium (Cisatracurium besilate) 2mg/ml | B3L78VA, B3M79VA |
Issue
The level of the degradation product Benzaldehyde is out of specification in the affected lots.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Omega Laboratories Ldt.
11177 rue Hamon
Montréal, QC
H3M 3E4
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type III
Identification number
RA-76972
Get notified
Receive notifications for new and updated recalls and alerts by category.